Cargando…
Corrigendum: Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients
Autores principales: | Tsai, Ming-Ju, Wu, Ping-Hsun, Sheu, Chau-Chyun, Hsu, Ya-Ling, Chang, Wei-An, Hung, Jen-Yu, Yang, Chih-Jen, Yang, Yi-Hsin, Kuo, Po-Lin, Huang, Ming-Shyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864416/ https://www.ncbi.nlm.nih.gov/pubmed/27169795 http://dx.doi.org/10.1038/srep25880 |
Ejemplares similares
-
Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients
por: Tsai, Ming-Ju, et al.
Publicado: (2016) -
Cysteinyl Leukotriene Pathway and Cancer
por: Tsai, Ming-Ju, et al.
Publicado: (2021) -
Adipokines and Cysteinyl Leukotrienes in the Pathogenesis of Asthma
por: Coffey, Michael J., et al.
Publicado: (2015) -
Montelukast: More than a Cysteinyl Leukotriene Receptor Antagonist?
por: Tintinger, Gregory R., et al.
Publicado: (2010) -
Cysteinyl Leukotriene Receptor Antagonists Associated With a Decreased Incidence of Cancer: A Retrospective Cohort Study
por: Jang, Ha Young, et al.
Publicado: (2022)